賽諾醫療(688108.SH)：目前成功推出多款國內國際領先的冠脈及神經介入產品，並在冠脈、神經以及結構性心臟病等介入治療重點領域持續佈局
格隆匯5月16日丨賽諾醫療(688108.SH)於2023年5月11日至5月12日、5月15日召開電話會議，問答環節中，就“公司如何看冠脈，神經以及結構性心臟病等板塊所處行業未來的發展？”，公司回覆稱，醫療器械行業處於快速發展期，需要通過持續的技術創新、堅實的循證醫學證據為驅動，不斷滿足臨牀需求、改善患者獲益，從而獲得商業的可持續發展。
冠脈介入醫療器械是我國血管介入器械中發展最成熟的細分市場。冠脈介入器械各細分領域在市場空間、進口替代率和競爭格局等方面均存在較大差異。結合心血管病患病人口數持續增加，冠脈介入治療手段不斷普及，基層醫院快速發展、國家組織器械耗材帶量採購以及國產醫療器械崛起等的推動作用，可以預見，未來中國冠心病介入治療病例數仍然會保持快速增長，冠脈介入耗材市場仍有巨大的發展潛力。
由於腦血管結構複雜，神經介入治療方案操作難度大、相關器械技術要求高，神經介入醫療器械產品在中國的發展尚處於起步階段。在中國神經介入器械市場中，跨國醫療器械廠商仍佔據絕大部分的市場份額，國產神經介入器械進口替代和產品創新潛力巨大。
結構性心臟病是近十餘年心血管疾病領域一個新型的亞專業，是涉及材料學、力學、生物學等高精尖技術的介入器械領域，其產品主要包括經皮瓣膜修復與置換產品和介入封堵術產品。伴隨着介入手術的不斷髮展，結構性心臟病器械逐漸成為一個高增長、大體量、高價值的成長行業。中國有140萬重度主動脈瓣膜返流患者，目前治療率不足1%；中國有550萬重度二尖瓣返流患者，治療率不足0.5%。整個行業尚處於起步階段，國內外大廠都在尋求技術突破，以尋求為結構性心臟病疾病治療，提供更好的解決方案。
目前公司成功推出多款國內國際領先的冠脈及神經介入產品，並在冠脈、神經以及結構性心臟病等介入治療重點領域持續佈局，致力於通過持續的研發投入和突破性創新，不斷滿足患者多樣的臨牀需求，打造高品質的創新醫療器械產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
